Drug intelligence / Profile preview

Onimex SF

Development stage: Unknown
Lead developer: Emcee Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Onimex SF** is a sugar-free oral fixed-dose cough syrup marketed by Emcee Pharmaceuticals in India. It contains ambroxol and guaifenesin and is used for cough with mucus: ambroxol acts as a mucolytic/secretolytic agent that helps loosen airway secretions, while guaifenesin is an expectorant that reduces mucus viscosity and facilitates its clearance by coughing. ([1mg.com](https://www.1mg.com/drugs/onimex-sf-30mg-200mg-syrup-sugar-free-273723))

Brand names: Onimex SF

Beyond the preview

Go deeper on Onimex SF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onimex SF.

Explore the full profile